Schizophrenia Drugs Market will Register Significant Gain

The increasing prevalence of chronic and mental disorder is a key factor expected to enable growth in the global schizophrenia drugs market size, says Fortune Business Insights in a report, titled “Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026.” The global schizophrenia drugs market was valued at USD 6.75 Billion in 2018 and is projected to reach USD 9.48 Billion by 2026, exhibiting a CAGR of 4.3% during the forecast period.

For more information in the analysis of this report, visit:
Key Segmentation of Schizophrenia Drugs Market:
Schizophrenia Drugs Market Segments by Therapeutic Class
·         Second Generation
·         Third Generation
·         Others
Schizophrenia Drugs Market Segments by Treatment
·         Oral
·         Injectable
Schizophrenia Drugs Market Segments by Distribution Channel
·         Hospital Pharmacies
·         Retail Pharmacies
·         Online Pharmacies
·         Others
By Geography
·         North America (U.S. and Canada)
·         Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
·         Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
·         Latin America (Brazil, Mexico, and Rest of Latin America)
Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)